178 related articles for article (PubMed ID: 16785120)
1. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
2. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
3. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
4. Current use of imatinib in the treatment of chronic myeloid leukemia.
O'Dwyer M
Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
[No Abstract] [Full Text] [Related]
5. Imatinib therapy in chronic myeloid leukemia.
Crossman LC; O'Brien SG
Hematol Oncol Clin North Am; 2004 Jun; 18(3):605-17, viii. PubMed ID: 15271395
[TBL] [Abstract][Full Text] [Related]
6. [The role of imatinib in the treatment of acute lymphoid leukemias].
Poros A; Lovas N
Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
[TBL] [Abstract][Full Text] [Related]
7. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Champlin RE; Kantarjian H
Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
[No Abstract] [Full Text] [Related]
8. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Chen F; Li L; Ma D; Yan S; Sun J; Zhang M; Ji C; Hou M
Leuk Res; 2010 Feb; 34(2):e75-7. PubMed ID: 19773083
[No Abstract] [Full Text] [Related]
9. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
Ozdemir E; Koc Y; Kansu E
Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
[No Abstract] [Full Text] [Related]
10. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
11. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
12. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Arancibia AM; Bendit I; Epelman S
Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
[No Abstract] [Full Text] [Related]
13. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
14. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
[TBL] [Abstract][Full Text] [Related]
15. Residual disease in chronic myeloid leukemia after induction of molecular remission.
Lange T; Niederwieser DW; Deininger MW
N Engl J Med; 2003 Oct; 349(15):1483-4. PubMed ID: 14534349
[No Abstract] [Full Text] [Related]
16. [Chronic myeloid leukemia].
Hochhaus A
Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
[No Abstract] [Full Text] [Related]
17. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
[No Abstract] [Full Text] [Related]
20. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
Yagasaki F
Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
